Canaccord


Esterline Technologies: Canaccord Upgrades Shares, Sees 17% Upside

In a report published today, Canaccord analyst Kenneth Herbert upgraded shares of Esterline Technologies Corp. (ESL) from Hold to Buy and raised the price target from $112.

Canaccord Reiterates Buy Rating On Oasis Petroleum, Raises PT to $64.00

In a research report published today, Canaccord analyst Stephen Berman maintained a Buy rating on Oasis Petroleum Inc. (OAS) and raised his price target to $64.

Canaccord Genuity Maintains Speculative Buy On Rubicon Minerals, Raises PT To C$1.80

In a research note issued this morning, Canaccord analyst Joe Mazumdar reiterated a “Speculative Buy” rating on Rubicon Minerals Corp. (RBY) and increased his price target to C$1.

Canaccord Analyst Upgrades AngioDynamics, Raises PT To $20

Canaccord analyst Jason Mills today upgraded his rating on AngioDynamics Inc. (ANGO) to Buy from Hold, and raised his price target to $20 from $16.

Canaccord Maintains Hold, $74 Price Target on Triumph Group

Canaccord analyst Kenneth Herbert maintains his Hold rating and $74 price target on Triumph Group, Inc. (TGI) following TGI’s announcement that is has settled all outstanding claims associated with …

Canaccord Reiterates Buy Rating For Black Diamond Following The Sale Of Gregory

In a report issued today, Canaccord analyst Camilo Lyon reiterated a Buy rating on shares of Black Diamond, Inc. (BDE) with a $17.

Canaccord Reiterates Buy On Gildan Activewear, Increases PT To $66

In a research note issued today, Canaccord analyst Derek Dley reiterated a Buy rating on Gildan Activewear Inc. (GIL) and raised his price target to $66.

Canaccord Reiterates Buy, $45 Price Target on Alere

Canaccord analyst Mark Massaro maintains his Buy rating and $45 price target on Alere (ALR) following the news that Alere has decided not to pursue an IPO …

Goodrich Petroleum Maintained With A Buy At Canaccord

In a research note issued today, Canaccord analyst Stephen Berman maintained coverage with a “Buy” rating on Goodrich Petroleum (GDP), and a price target of $33.00 a share.

Roth Capital Reiterates Buy Rating On LeMaitre Vascular Following Recent Financing

In a research note issued this morning, Roth Capital analyst Chris Lewis reiterated coverage with a “Buy” rating on LeMaitre Vascular, Inc. (LMAT), and a price target of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts